Bipolar disorder, in partial remission, most recent episode hypomanic
Methodology & AI Transparency ⓘ
Bipolar disorder, in partial remission, most recent episode hypomanic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Bipolar disorder, in partial remission, most recent episode hypomanic is an ICD-10-CM indexed diagnosis (F31.71) within Depression, Bipolar & Mood Disorders.
- 2 Real-world patient consensus: Mapped to Depression, Bipolar & Mood Disorders under ICD-10-CM F31.71 for Bipolar disorder, in partial remission, most recent episode hypomanic clinical workups.
- 3 Typical cash cost range: Clinicians assessing Bipolar disorder, in partial remission, most recent episode hypomanic focus on prefrontal-limbic circuit dysregulation [Bipolar disorder, in partial remission, most recent episode hypomanic F31.71] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Bipolar disorder, in partial remission, most recent episode hypomanic monitoring tracks Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: & RBC Folate) toward 25(OH)D 40 – 65 ng/mL (F31.71).
Ask our AI Specialists anything about Bipolar disorder, in partial remission, most recent episode hypomanic
What Is Bipolar disorder, in partial remission, most recent episode hypomanic?
Bipolar disorder, in partial remission, most recent episode hypomanic is an ICD-10-CM indexed diagnosis (F31.71) within Depression, Bipolar & Mood Disorders. Clinical evaluation centers on validated longitudinal mood in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: rating scales (PHQ-9) alongside serial Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: & RBC Folate) tracking (25(OH)D 40 – 65 ng/mL (F31.71)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
In Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71), physiological disruption stems from prefrontal-limbic circuit dysregulation [Bipolar disorder, in partial remission, most recent episode hypomanic F31.71], informing Depression, Bipolar & Mood Disorders protocols that track PHQ-9 Symptom Severity in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: Score) (< 4 (clinical remission) (F31.71)).
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71): disrupted sleep architecture [Bipolar disorder, in partial remission, most recent episode hypomanic F31.71]
- • Secondary Bipolar disorder, in partial remission, most recent episode hypomanic clinical sign: slowed concentration, indecisiveness, in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: and physical heaviness)
- • Symptom flares in Bipolar disorder, in partial remission, most recent episode hypomanic correlating with Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: & RBC Folate) deviation outside 25(OH)D 40 – 65 ng/mL (F31.71)
- • Functional depression & mood impact requiring validated longitudinal mood in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: rating scales (PHQ-9) evaluation (F31.71)
Bipolar disorder, in partial remission, most recent episode hypomanic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.71 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.71) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: Score) | < 4 (clinical remission) (F31.71) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, in partial remission, most recent episode hypomanic (F31.71: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.71) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, in partial remission, most recent episode hypomanic
Treatment selection for Bipolar disorder, in partial remission, most recent episode hypomanic depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, in partial remission, most recent episode hypomanic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? These data suggest that patients with high negative affectivity respond preferentially to antidepressants that selectively enhance serotonin neurotransmission. The Journal of clinical psychiatry • 2014-09-15 • Randomized Controlled Trial | N = 245 | 88/100 | PMID 25295437 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Lumateperone for Major Depressive Episodes Associated With Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders. The American journal of psychiatry • 2021-12-15 • Phase III Randomized Trial | N = 188 | 88/100 | PMID 34551584 ↗ |
Bipolar disorder, in partial remission, most recent episode hypomanic Patient Community & “People Like Me” Threads
Filter Bipolar disorder, in partial remission, most recent episode hypomanic community threads and patient logs by age, biological sex, dosage, and treatment duration.